Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Reduced Dose Adjuvated IPV-Al SSI in Infants
NCT02347423Phase 2Completed
- Sponsor
- Statens Serum Institut
- Start
- Feb 2015
- Primary completion
- Sep 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Picovax in poliomyelitis, sponsored by Statens Serum Institut. Started Feb 2015; status: completed.
02
Drugs
Picovax
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT02347423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347423.